RT Journal Article
SR Electronic
T1 Using test positivity and reported case rates to estimate state-level COVID-19 prevalence in the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.07.20208504
DO 10.1101/2020.10.07.20208504
A1 Weihsueh A. Chiu
A1 Martial L. Ndeffo-Mbah
YR 2020
UL http://medrxiv.org/content/early/2020/10/12/2020.10.07.20208504.abstract
AB Accurate estimates of the prevalence of infection are essential for evaluating and informing public health responses to the ongoing COVID-19 pandemic in the United States (US), but reliable, timely prevalence data based on representative population sampling are unavailable, and reported case and test positivity rates may provide strongly biased estimates. A single parameter semi-empirical model was developed, calibrated, and validated with prevalence predictions from two independent data-driven mathematical epidemiological models, each of which was separately validated using available cumulative infection estimates from recent state-wide serological testing in 6 states. The analysis shows that individually, reported case rates and test positivity rates may provide substantially biased estimates of COVID-19 prevalence and transmission trends in the U.S. However, the COVID-19 prevalence for U.S. states from March-July, 2020 is well approximated, with a 7-day lag, by the geometric mean of reported case and test positivity rates averaged over the previous 14 days. Predictions of this semi-empirical model are at least 10-fold more accurate than either test positivity or reported case rates alone, with accuracy that remains relatively constant across different US states and varying testing rates. The use of this simple and readily-available surrogate metric for COVID-19 prevalence, that is more accurate than test positivity and reported case rates and does not rely on mathematical modeling, may provide more reliable information for decision makers to make effective state-level decisions as to public health responses to the ongoing COVID-19 pandemic in the US.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Science Foundation (NSF DEB RAPID 2028632) and National Institutes of Health, National Institute of Environmental Health Sciences (P30 ES029067). The funders have no role in the design of the study, collection, analysis, and interpretation of data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB was not requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe codes and data used to generate our results are available on GitHubhttps://github.com/wachiuphd/COVID-19-US-Semi-Empirical